MX2009011750A - Promotores que exhiben especifidad de celula endotelial y metodos para usarlos para la regulacion de angiogenesis. - Google Patents

Promotores que exhiben especifidad de celula endotelial y metodos para usarlos para la regulacion de angiogenesis.

Info

Publication number
MX2009011750A
MX2009011750A MX2009011750A MX2009011750A MX2009011750A MX 2009011750 A MX2009011750 A MX 2009011750A MX 2009011750 A MX2009011750 A MX 2009011750A MX 2009011750 A MX2009011750 A MX 2009011750A MX 2009011750 A MX2009011750 A MX 2009011750A
Authority
MX
Mexico
Prior art keywords
methods
endothelial cell
angiogenesis
regulation
same
Prior art date
Application number
MX2009011750A
Other languages
English (en)
Spanish (es)
Inventor
Dror Harats
Shoshana Greenberger
Eyal Breitbart
Livnat Bangio
Michael Peled
Original Assignee
Vascular Biogenics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vascular Biogenics Ltd filed Critical Vascular Biogenics Ltd
Publication of MX2009011750A publication Critical patent/MX2009011750A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
MX2009011750A 2007-04-30 2008-04-27 Promotores que exhiben especifidad de celula endotelial y metodos para usarlos para la regulacion de angiogenesis. MX2009011750A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/790,992 US20070286845A1 (en) 2000-11-17 2007-04-30 Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
PCT/IL2008/000543 WO2008132729A2 (en) 2007-04-30 2008-04-27 Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis

Publications (1)

Publication Number Publication Date
MX2009011750A true MX2009011750A (es) 2010-04-27

Family

ID=38895566

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009011750A MX2009011750A (es) 2007-04-30 2008-04-27 Promotores que exhiben especifidad de celula endotelial y metodos para usarlos para la regulacion de angiogenesis.

Country Status (11)

Country Link
US (2) US20070286845A1 (cg-RX-API-DMAC7.html)
EP (1) EP2152317A4 (cg-RX-API-DMAC7.html)
JP (1) JP2010525805A (cg-RX-API-DMAC7.html)
KR (1) KR101525548B1 (cg-RX-API-DMAC7.html)
CN (2) CN101808669A (cg-RX-API-DMAC7.html)
AU (1) AU2008243817B2 (cg-RX-API-DMAC7.html)
CA (1) CA2685394A1 (cg-RX-API-DMAC7.html)
MX (1) MX2009011750A (cg-RX-API-DMAC7.html)
NZ (1) NZ581511A (cg-RX-API-DMAC7.html)
WO (1) WO2008132729A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200908331B (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003222427B8 (en) 2000-11-17 2010-04-29 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
US20100282634A1 (en) * 2000-11-17 2010-11-11 Dror Harats Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis
US8039261B2 (en) * 2000-11-17 2011-10-18 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US8071740B2 (en) 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US6838452B2 (en) 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
EP1436313B1 (en) * 2001-10-19 2010-09-22 Vascular Biogenics Ltd. Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy
WO2010005850A1 (en) * 2008-07-08 2010-01-14 The J. David Gladstone Institutes Methods and compositions for modulating angiogenesis
SG182367A1 (en) * 2010-01-05 2012-08-30 Vascular Biogenics Ltd Methods for use of a specific anti-angiogenic adenoviral agent
SG182366A1 (en) * 2010-01-05 2012-08-30 Vascular Biogenics Ltd Compositions and methods for treating glioblastoma gbm
EP2523681A1 (en) * 2010-01-12 2012-11-21 Vascular Biogenics Ltd. Methods of producing adenovirus vectors and viral preparations generated thereby
WO2012052878A1 (en) 2010-10-19 2012-04-26 Vascular Biogenics Ltd. Isolated polynucleotides and nucleic acid constructs for directing expression of a gene-of-interest in cells
CN103339262A (zh) * 2010-10-28 2013-10-02 弗吉尼亚联邦大学 具有治疗作用的癌症成像：治疗诊断学
WO2012112586A1 (en) 2011-02-14 2012-08-23 Revivicor, Inc. Genetically modified pigs for xenotransplantation of vascularized xenografts and derivatives thereof
LT2908865T (lt) 2012-10-17 2019-01-10 Vascular Biogenics Ltd. Fas-chimerą ekspresuojantis adenovirusas ir jo panaudojimas vėžio gydymo būduose
ES2774964T3 (es) 2013-02-04 2020-07-23 Vascular Biogenics Ltd Métodos para inducir la capacidad de respuesta a un agente antiangiogénico
CN107630004B (zh) 2017-09-01 2021-01-15 康希诺生物股份公司 降低可复制性腺病毒产生的细胞株及构建方法和应用
CN111356480A (zh) 2017-10-20 2020-06-30 脉管生物生长有限公司 用于抗血管生成剂疗法的诊断方法
CA3131936A1 (en) 2019-03-13 2020-09-17 Vascular Biogenics Ltd. Methods of anti-tumor therapy
BR112021020225A2 (pt) 2019-04-12 2021-12-07 Vascular Biogenics Ltd Métodos de terapia antitumoral
CN110714028B (zh) * 2019-11-04 2021-08-31 中国人民解放军第四军医大学 可控性上调Ang-(1-7)靶向性防治低氧性肺动脉高压的表达载体
EP3995569A1 (en) 2020-11-10 2022-05-11 Vessl Therapeutics Ltd Methods of preconditioning vascular cells for transduction, methods of transduction and methods of preserving transduced cells
WO2023044100A1 (en) * 2021-09-20 2023-03-23 Revivicor, Inc. Multitran scenic pigs comprising ten genetic modifications for xenotransplantation
FR3158516A1 (fr) * 2024-01-23 2025-07-25 Asfalia Biologics Production de vecteurs toxiques

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US207985A (en) * 1878-09-10 Improvement in grain-separators
US4866042A (en) * 1987-11-18 1989-09-12 Neuwelt Edward A Method for the delivery of genetic material across the blood brain barrier
US5464764A (en) * 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US6337209B1 (en) * 1992-02-26 2002-01-08 Glaxo Wellcome Inc. Molecular constructs containing a carcinoembryonic antigen regulatory sequence
CA2108144A1 (en) * 1991-03-06 1992-09-07 Jack A. Roth Methods and compositions for the selective inhibition of gene expression
US5635385A (en) * 1993-09-15 1997-06-03 Temple University-Of The Commonwealth System Of Higher Education Multi-unit ribozyme inhibition of oncogene gene expression
US6037329A (en) * 1994-03-15 2000-03-14 Selective Genetics, Inc. Compositions containing nucleic acids and ligands for therapeutic treatment
US6579697B1 (en) * 1995-05-11 2003-06-17 Yeda Research And Development Co. Ltd. Modulator of TNF/NGF superfamily receptors and soluble oligomeric TNF/NGF superfamily receptors
US8715645B2 (en) * 1994-05-27 2014-05-06 The Regents Of The University Of Colorado Viral vectors encoding apoptosis-inducing proteins and methods for making and using the same
US5747340A (en) * 1994-06-03 1998-05-05 Syntex (U.S.A.) Inc. Targeted gene expression using preproendothelin-1 promoters
US5906827A (en) * 1994-06-03 1999-05-25 Creative Biomolecules, Inc. Matrix for the manufacture of autogenous replacement body parts
GB9506466D0 (en) * 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US5734039A (en) * 1994-09-15 1998-03-31 Thomas Jefferson University Antisense oligonucleotides targeting cooperating oncogenes
US5712149A (en) * 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
US5792453A (en) * 1995-02-28 1998-08-11 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
CA2188575A1 (en) * 1995-02-28 1996-09-06 H. Kirk Hammond Gene transfer-mediated angiogenesis therapy
US5916763A (en) * 1995-11-09 1999-06-29 The Regents Of The University Of California Promoter for VEGF receptor
ATE291588T1 (de) * 1996-11-08 2005-04-15 Oklahoma Med Res Found Endothel-spezifischer expression unter einfluss von epcr kontrollelementen
BR9713661A (pt) * 1996-12-30 2000-10-24 Battelle Memorial Institute Formulação e método para o tratamento de neoplasmas por inalação
US6206917B1 (en) * 1997-05-02 2001-03-27 St. Jude Medical, Inc. Differential treatment of prosthetic devices
WO1999006563A1 (en) * 1997-07-30 1999-02-11 Emory University Novel bone mineralization proteins, dna, vectors, expression systems
EP0909532A1 (en) * 1997-10-16 1999-04-21 Development Center For Biotechnology Environmentally compatible porous material comprising beneficial nematodes and its preparation
US6183737B1 (en) * 1997-10-30 2001-02-06 The General Hospital Corporation Bonding of cartilage pieces using isolated chondrocytes and a biological gel
US5882893A (en) * 1997-12-04 1999-03-16 Millennium Pharmaceuticals, Inc. Nucleic acids encoding muscarinic receptors and uses therefor
US6417168B1 (en) * 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
US6180355B1 (en) * 1998-05-07 2001-01-30 University Of Maryland, Baltimore Method for diagnosing and treating chronic pelvic pain syndrome
US6239151B1 (en) * 1998-06-26 2001-05-29 Hoffmann-La Roche Inc. Compounds as inhibitor of tumor necrosis factor alpha release
US6545048B1 (en) * 1999-06-29 2003-04-08 California Institute Of Technology Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity
US6576265B1 (en) * 1999-12-22 2003-06-10 Acell, Inc. Tissue regenerative composition, method of making, and method of use thereof
US6479064B1 (en) * 1999-12-29 2002-11-12 Children's Medical Center Corporation Culturing different cell populations on a decellularized natural biostructure for organ reconstruction
US6376244B1 (en) * 1999-12-29 2002-04-23 Children's Medical Center Corporation Methods and compositions for organ decellularization
US6265216B1 (en) * 2000-01-20 2001-07-24 Isis Pharmaceuticals, Inc. Antisense modulation of cot oncogene expression
US6866864B2 (en) * 2000-03-20 2005-03-15 Ahmed Mousa Compositions and methods of use in the treatment of angiogenesis and vascular-related disorders
US6652583B2 (en) * 2000-04-07 2003-11-25 Rhode Island Hospital Cardiac valve replacement
AU2003222427B8 (en) * 2000-11-17 2010-04-29 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
US8039261B2 (en) * 2000-11-17 2011-10-18 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US20100282634A1 (en) * 2000-11-17 2010-11-11 Dror Harats Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis
US8071740B2 (en) * 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US7067649B2 (en) * 2000-11-17 2006-06-27 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
US20040048280A1 (en) * 2000-11-17 2004-03-11 Dror Harats Promoters exhibiting endothelial cell specificity and methods of using same
EP1207205A1 (en) * 2000-11-20 2002-05-22 Crucell Holland B.V. Adenoviral replicons
US6438802B1 (en) * 2001-06-07 2002-08-27 Randolph Scott Beeman Locking mechanism and method for securely fastening resilient cords and tubing
CN1195056C (zh) * 2001-07-12 2005-03-30 钱其军 一种在肿瘤细胞中特异性增殖及高效表达抗癌基因的重组病毒及其构建方法
EP1436313B1 (en) * 2001-10-19 2010-09-22 Vascular Biogenics Ltd. Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy
US9738907B2 (en) * 2002-02-01 2017-08-22 Oxford Biomedica (Uk) Limited Viral vector
WO2003066860A1 (fr) * 2002-02-04 2003-08-14 Takeda Chemical Industries, Ltd. Inhibiteurs d'angiogenese
CN1424401A (zh) * 2003-01-06 2003-06-18 李川源 有条件复制型腺病毒及其构建方法和用途

Also Published As

Publication number Publication date
AU2008243817A1 (en) 2008-11-06
US20070286845A1 (en) 2007-12-13
US20140155467A1 (en) 2014-06-05
ZA200908331B (en) 2010-12-29
JP2010525805A (ja) 2010-07-29
AU2008243817B2 (en) 2013-09-19
EP2152317A4 (en) 2012-11-14
CN103276015A (zh) 2013-09-04
KR20100017114A (ko) 2010-02-16
CN101808669A (zh) 2010-08-18
EP2152317A2 (en) 2010-02-17
WO2008132729A3 (en) 2009-10-22
WO2008132729A2 (en) 2008-11-06
CA2685394A1 (en) 2008-11-06
KR101525548B1 (ko) 2015-06-15
NZ581511A (en) 2012-02-24

Similar Documents

Publication Publication Date Title
MX2008010859A (es) Promotores que exhiben especificidad de celula endotelial y metodos para usarlos para la regulacion de angiogenesis.
MX2009011750A (es) Promotores que exhiben especifidad de celula endotelial y metodos para usarlos para la regulacion de angiogenesis.
SG171581A1 (en) Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
MX2021011351A (es) Tecnologias utiles para la preparacion de oligonucleotidos.
UA104626C2 (ru) Анти-vegf антитело и его применение
MX2011012757A (es) Produccion biocatalitica de ambroxan.
JO2939B1 (en) Tetrahydro-pyrido-pyrimidine derivatives
IN2012DN00568A (cg-RX-API-DMAC7.html)
MY156816A (en) High affinity human antibodies to human angiopoietin-2
GB2441488A (en) Suspension culture of human embryonic stem cells
MX2012003770A (es) Metodos para la modulacion de autofagia a traves de la modulacion de productos de genes que aumentan la autofagia.
UA97816C2 (en) Compounds modulating c-kit and/or c-fms activity and use thereof
MX359833B (es) Anticuerpos anti-tie2 y usos de los mismos.
MY165103A (en) Recombinant microorganisms and methods of use thereof
MY170922A (en) Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
EA201291107A1 (ru) Соединения, ингибирующие металлоферменты
TN2014000067A1 (en) Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
WO2009120762A3 (en) Human cardiovascular progenitor cells
UA102432C2 (ru) Цитотоксичные конъюгаты с соединением, которое связывает рецептор нейропептиду y
GB201011589D0 (en) Therapeutic cells
EP4003585C0 (en) BIOREACTORS FOR CULTIVATING MICROORGANISMS
IL284678B1 (en) Bioreactors for microorganism growth
IN2013MN00733A (cg-RX-API-DMAC7.html)
MY157007A (en) Novel possibility of controlling giardiosis
MX2013012128A (es) Medio de cultivo para celulas madre mesenquimales humanas.

Legal Events

Date Code Title Description
FG Grant or registration